In a report released on May 9, Thomas Smith from Leerink Partners reiterated a Buy rating on Aclaris Therapeutics (ACRS – Research Report), with a price target of $7.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thomas Smith has given his Buy rating due to a combination of factors including Aclaris Therapeutics’ promising clinical pipeline and strategic developments. The company has reported progress with its newly in-licensed biologics from Biosion, particularly bosakitug, which is set to enter a Phase 2 trial for atopic dermatitis in the second quarter of 2025. This trial, along with ongoing studies by their partner CTTQ in China, provides strong clinical evidence supporting the potential of bosakitug in various indications.
Moreover, Aclaris is focusing its efforts on dermatological immuno-inflammatory conditions while seeking partnerships for respiratory indications, which could enhance its strategic positioning. The company also announced the initiation of trials for ATI-052 and expects results from the ATI-2138 trial in mid-2025, which could expand its treatment portfolio. These developments, coupled with a solid financial position, underpin Smith’s optimistic outlook on Aclaris Therapeutics’ future growth potential.
In another report released on May 9, Scotiabank also maintained a Buy rating on the stock with a $9.00 price target.